Title: Giant Congenital Melanocytic Nevus in Newborn: Case Report
Authors: Swati Mahajan, Mohit Bajaj, Amar Singh Thakur, Ajay Vaid
DOI: https://dx.doi.org/10.18535/jmscr/v8i4.02
Abstract
Congenital melanocytic nevus is usually defined as a melanocytic lesion which presents within 2 years of birth. Giant congenital melanocytic nevus (GCMN) has incidence of approximately <1:20,000 newborns. Despite being rare, GCMN is significant because of its association with severe complications such as malignant melanoma and neurocutaneous melanosis. GCMN presents as a brown lesion, with flat or mammilated surface, well-demarcated borders and hypertrichosis. Congenital melanocytic nevus is primarily a clinical diagnosis. Although GCMN is recognized as a risk factor for the development of melanoma, the precise magnitude of this risk is still controversial. The estimated lifetime risk of developing melanoma varies from 5 to 10%. On account of these uncertainties and the size of the lesions, the management of giant congenital melanocytic nevus needs individualization. Treatment may include surgical and non-surgical procedures, psychological intervention and/or clinical follow-up, with special attention to changes in color, texture or on the surface of the lesion. Indication for surgery in GCMN is the development of a malignant neoplasm on the lesion.
Keywords: Nevi; melanomas; Nevus, pigmented; Skin neoplasm.
References
- Grichnik JM, Rhodes AR, Sober AJ. Benign neoplasias and hyperplasias of melanocytes. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Lefell DJ, editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw-Hill; 2008. p. 1099-122.
- Castilla EE, da Graça Dutra M, Orioli-Parreiras IM. Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. Br J Dermatol. 1981;104:307-15
- Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics. 1999; 104: 1042-5.
- Rhodes AR. Melanocytic precursors of cutaneous melanoma. Estimated risks and guidelines for management. Med Clin North Am. 1986;70:3-37.
- Kaplan EN. The risk of malignancy in large congenital nevi. Plast Reconstr Surg. 1974;53:421-8.
- Slutsky JB, Barr JM, Femia AN, Marghoob AA. Large congenital melanocytic nevi: associated risks and management considerations. Semin Cutan Med Surg.2010;29:79-84.
- Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155:1-8.
- Strauss RM, Newton Bishop JA. Spontaneous involution of congenital melanocytic nevi of the scalp. J Am Acad Dermatol. 2008;58:508-11.
- Kopf A, Bart R, Hennessey P. Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol. 1979;1:123-30.
- Takayama H, Nagashima Y, Hara M, Takagi H, Mori M, Merlino G, et al. Immunohistochemical detection of the c-met proto-oncogene product in the congenital melanocytic nevus of an infant with neurocutaneous melanosis. J Am Acad Dermatol.2001;44:538-40.
- Martínez-Granero MA, Pascual-Castroviejo I. Neurocutaneous melanosis. Rev Neurol. 1997;25:S265-8.
- Chung C, Forte A, Narayan D, Persing J. Giant nevi: a review. J Craniofac Surg. 2006;17:1210-5.
- Price H, Schaffer J. Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clin Dermatol. 2010;28:293-302.